| Schedule of financial information by reportable segment |
The following is financial information relating to the Company's reportable segments (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter Ended |
|
Six Months Ended |
|
|
December 31, |
|
December 31, |
|
|
2024 |
|
2023 |
|
2024 |
|
2023 |
Net sales: |
|
|
|
|
|
|
|
|
|
|
|
|
Protein Sciences |
|
$ |
211,551 |
|
$ |
197,670 |
|
$ |
416,086 |
|
$ |
402,325 |
Diagnostics and Spatial Biology |
|
|
84,135 |
|
|
75,408 |
|
|
167,327 |
|
|
148,204 |
Other revenue(1) |
|
|
1,849 |
|
|
— |
|
|
4,152 |
|
|
— |
Intersegment |
|
|
(504) |
|
|
(480) |
|
|
(1,076) |
|
|
(996) |
Consolidated net sales |
|
$ |
297,031 |
|
$ |
272,598 |
|
$ |
586,489 |
|
$ |
549,533 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income: |
|
|
|
|
|
|
|
|
|
|
|
|
Protein Sciences |
|
$ |
87,112 |
|
$ |
79,586 |
|
$ |
167,653 |
|
$ |
167,947 |
Diagnostics and Spatial Biology |
|
|
3,240 |
|
|
4,556 |
|
|
7,517 |
|
|
5,082 |
Segment operating income |
|
$ |
90,352 |
|
$ |
84,142 |
|
$ |
175,170 |
|
$ |
173,029 |
Costs recognized on sale of acquired inventory |
|
|
(185) |
|
|
(183) |
|
|
(373) |
|
|
(364) |
Amortization of intangibles |
|
|
(18,559) |
|
|
(19,769) |
|
|
(38,300) |
|
|
(39,620) |
Acquisition related expenses and other |
|
|
(2,010) |
|
|
525 |
|
|
(3,523) |
|
|
1,114 |
Certain litigation charges |
|
|
(1,386) |
|
|
— |
|
|
(1,678) |
|
|
— |
Impairment of assets held-for-sale |
|
|
— |
|
|
(6,038) |
|
|
— |
|
|
(6,038) |
Stock based compensation, inclusive of employer taxes |
|
|
(15,238) |
|
|
(12,958) |
|
|
(25,875) |
|
|
(24,453) |
Restructuring and restructuring-related costs |
|
|
(3,287) |
|
|
(5,518) |
|
|
(14,309) |
|
|
(5,607) |
Corporate general, selling, and administrative expenses |
|
|
(1,641) |
|
|
(2,197) |
|
|
(3,227) |
|
|
(4,195) |
Impact of business held-for-sale(1) |
|
|
(627) |
|
|
— |
|
|
(479) |
|
|
— |
Consolidated operating income |
|
$ |
47,419 |
|
$ |
38,004 |
|
$ |
87,406 |
|
$ |
93,866 |
(1) Includes the quarterly results of a business that has met the held-for-sale criteria since December 31, 2023.
|